Andrea Gross

National Cancer Institute

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (10)

Laura J Klesse

University of Texas Southwestern Medical School

UNITED STATES

View details

Jonathan Payne

University of Melbourne

AUSTRALIA

View details

Jaishri Blakeley

Johns Hopkins University

UNITED STATES

View details

Elliot Stieglitz

Associate Professor

UCSF Benioff Children's Hospital

UNITED STATES

View details

Mary Jane Ong

National Institutes of Health

UNITED STATES

View details

Kaleb Yohay

Professor of Neurology and Pediatrics (Clinical)

NYU Langone Medical Center

UNITED STATES

View details

Brian Weiss

Division Chief

Riley Hospital for Children at Indiana University Health

UNITED STATES

View details

Amanda Rhodes

National Institutes of Health

UNITED STATES

View details

Steven Angus

Assistant Professor

Indiana State University

UNITED STATES

View details

Vanessa Merker

Assistant Professor

Massachusetts General Hospital

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrea Gross

Research Interests

Explore related searches

Contact this professor

Articles (16)

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas

A Mixed Methods Study of Medication Adherence in Adults with Neurofibromatosis Type 1 (NF1) on a Clinical Trial of Selumetinib

Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1

Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration

Anthropometric measurements of children with neurofibromatosis type I: impact of plexiform neurofibroma volume and treatment

Challenges in determining the malignant potential of atypical neurofibromas (aNF) using histopathologic features and the potential need for <i>CDKN2A/2B</i> testing: a case report

Challenges in determining the malignant potential of atypical neurofibromas (aNF) using histopathologic features and the potential need for CDKN2A/2B testing: a case report

Development and pilot validation of a novel disfigurement severity scale for plexiform neurofibromas in children with neurofibromatosis type 1

Genomic ascertainment to quantify prevalence and cancer risk in adults with pathogenic and likely pathogenic germline variants in RASopathy genes

Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma

Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Collaborators (10)

Laura J Klesse

Jonathan Payne

Jaishri Blakeley

Elliot Stieglitz

Mary Jane Ong

Kaleb Yohay

Brian Weiss

Amanda Rhodes

Steven Angus

Vanessa Merker

Make your next move.